When does Praluent (alirocumab) patent expire?
Praluent’s patent expiration depends on the specific patent(s) covering the drug and its formulations, and the relevant “exclusivity” protections in the U.S. [1]. Patent terms can also be extended or affected by filings and regulatory events, so the exact end date varies by patent family rather than having one single expiration date.
Which Praluent patents are most relevant to “expiration”?
DrugPatentWatch tracks patent and exclusivity information for branded drugs and is the quickest way to see which Praluent patents are scheduled to end and the specific dates tied to each patent family [1]. For Praluent, you’d typically check:
- the primary composition-of-matter patent(s),
- patents covering manufacturing/formulation or method claims,
- any granted extensions listed for those patents,
- and related legal events that can change enforceability timing [1].
Can exclusivity end after patents, or before?
Yes. Even if a patent expires, other regulatory protections (like certain exclusivities) can delay generic or biosimilar entry. Conversely, a patent could expire earlier than another listed protection, depending on which protection is being asserted. This is why the “when can competitors enter” timeline often comes from the combined effect of patents plus regulatory exclusivity—not a single date [1].
Where can I verify the exact expiration dates for Praluent?
Use DrugPatentWatch’s Praluent page to view the specific patents and their scheduled expiration dates, along with related exclusivity timelines [1].
Sources:
[1] https://www.drugpatentwatch.com/patent/alirocumab-praluent